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abstract
PURPOSE To provide guidance on the clinical management of dyspnea in adult patients with advanced cancer.
METHODS ASCO convened an Expert Panel to review the evidence and formulate recommendations. An Agency
for Healthcare Research and Quality (AHRQ) systematic review provided the evidence base for non-
pharmacologic and pharmacologic interventions to alleviate dyspnea. The review included randomized con-
trolled trials (RCTs) and observational studies with a concurrent comparison group published through early May
2020. The ASCO Expert Panel also wished to address dyspnea assessment, management of underlying
conditions, and palliative care referrals, and for these questions, an additional systematic review identified RCTs,
systematic reviews, and guidelines published through July 2020.
RESULTS The AHRQ systematic review included 48 RCTs and two retrospective cohort studies. Lung cancer and
mesothelioma were the most commonly addressed types of cancer. Nonpharmacologic interventions such as
fans provided some relief from breathlessness. Support for pharmacologic interventions was limited. A meta-
analysis of specialty breathlessness services reported improvements in distress because of dyspnea.
RECOMMENDATIONS A hierarchical approach to dyspnea management is recommended, beginning with
dyspnea assessment, ascertainment and management of potentially reversible causes, and referral to an in-
terdisciplinary palliative care team. Nonpharmacologic interventions that may be offered to relieve dyspnea
include airflow interventions (eg, a fan directed at the cheek), standard supplemental oxygen for patients with
hypoxemia, and other psychoeducational, self-management, or complementary approaches. For patients who
derive inadequate relief from nonpharmacologic interventions, systemic opioids should be offered. Other
pharmacologic interventions, such as corticosteroids and benzodiazepines, are also discussed.
Additional information is available at www.asco.org/supportive-care-guidelines.
J Clin Oncol 39:1389-1411. © 2021 by American Society of Clinical Oncology
INTRODUCTION
Dyspnea, also known as breathlessness or air hunger,
is a subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary in
intensity1 (see Table 1 for a list of definitions). It is one
of the most common and distressing symptoms af-
fecting patients with advanced cancer.2 In a meta-
analysis that included more than 10,000 patients with
advanced cancer, 10%-70% of patients reported
dyspnea.2 Dyspnea typically increases in prevalence
and intensity as patients approach the last weeks to
days of life.3-6 In a longitudinal observational study of
patients with lung cancer, dyspnea was consistently
ranked as the most distressing symptom.7 The burden
of dyspnea is further compounded by other related
symptoms such as fatigue, anxiety, and depression,
resulting in functional limitation, compromised quality
of life, and increased informal (family) caregiver
burden.8 In the advanced cancer setting, the pres-
ence of dyspnea, particularly at rest, indicates a poor
prognosis (typically less than a few months) and has
important clinical implications.9 First, a patient’s
prognosis could significantly affect recommendations
regarding assessments and treatments. Second, cli-
nicians need to routinely engage in serious illness
conversations with the patients and their caregivers to
ensure prognostic understanding, discuss how
dyspnea should be managed (eg, cancer treatments





























Volume 39, Issue 12 1389
Downloaded from ascopubs.org by 59.167.129.144 on November 10, 2021 from 059.167.129.144
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
THE BOTTOM LINE
Management of Dyspnea in Advanced Cancer: ASCO Guideline
Guideline Question
How should dyspnea be managed in adult patients with advanced cancer?
Target Population
Adult patients with advanced cancer and dyspnea.
Target Audience
Clinicians who provide care to adult patients with cancer, as well as patients and informal (family) caregivers.
METHODS
An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the
clinical literature.
Recommendations
1. Screening and assessment
1.1. Clinicians should perform systematic assessment of dyspnea at every inpatient and outpatient encounter
in patients with advanced cancer using validated patient-reported outcome measures (good practice
statement).
1.2. For patients who are unable to self-report, clinicians should use a validated observation measure (good practice
statement).
1.3. Whenever possible, patients with dyspnea should undergo a comprehensive evaluation for the severity, chronicity,
potential causes, triggers, and associated symptoms, as well as emotional and functional impact (good practice
statement).
Note. Examples of validated and easy-to-use assessment tools are provided in the Data Supplement, online only.
2. Treatment of underlying causes
2.1. Patients with potentially reversible, common etiologies of dyspnea such as pleural effusion, pneumonia, airway
obstruction, anemia, asthma, chronic obstructive pulmonary disease (COPD) exacerbation, pulmonary embolism,
or treatment-induced pneumonitis should be given goal-concordant treatment(s) consistent with their wishes,
prognosis, and overall health status (good practice statement).
2.2. Patients with dyspnea because of underlying malignancy (eg, lymphangitic carcinomatosis, atelectasis because of
large pulmonary mass, malignant pleural effusion) may benefit from cancer-directed treatments if consistent with
their wishes, prognosis, and overall health status (good practice statement).
2.3. Patients with underlying comorbidities such as COPD or heart failure should have the management of these
conditions optimized (good practice statement).
3. Referral to palliative care
3.1. Patients with advanced cancer and dyspnea should be referred to an interprofessional palliative care team where
available (type: evidence based; evidence quality: intermediate; strength of recommendation: strong).
4. Nonpharmacologic interventions
4.1. Airflow interventions such as directing a fan at the cheek (trigeminal nerve distribution) should be offered (type:
evidence-based; evidence quality: intermediate; strength of recommendation: moderate).
4.2. Standard supplemental oxygen should be available for patients with hypoxemia who are experiencing dyspnea (ie,
SpO2 # 90% on room air) (type: evidence-based; evidence quality: intermediate; strength of recommendation:
moderate).
4.3. Supplemental oxygen is not recommended when SpO2 . 90% (type: evidence-based; evidence quality: inter-
mediate; strength of recommendation: moderate).
4.4. A time-limited therapeutic trial of high-flow nasal cannula oxygen therapy, if available, may be offered to patients
who have significant dyspnea and hypoxemia despite standard supplemental oxygen (type: evidence-based;
evidence quality: low; strength of recommendation: moderate).
4.5. A time-limited therapeutic trial of noninvasive ventilation, if available, may be offered to patients who have
significant dyspnea despite standard measures and do not have contraindications (type: evidence-based; evi-
dence quality: low; strength of recommendation: moderate).
(continued on following page)
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The purpose of this guideline is to provide evidence-based
recommendations for the management of dyspnea in pa-
tients with advanced cancer. Similar to pain, chronic
dyspnea is a multidimensional construct with physical,
emotional, and social components.1,10 Thus, a variety of
pharmacologic and nonpharmacologic therapies are needed
to address the multidimensional sources of suffering.
This ASCO clinical practice guideline is formulated based
on a recently completed systematic review supported
by the Agency for Healthcare Research and Quality
(AHRQ)11,12 and provides practical recommendations
taking into account the clinical context as well as risks and
benefits of each intervention with input from an interpro-
fessional group of expert clinicians and researchers.
It is important to note that few adequately powered ran-
domized controlled trials (RCTs) on dyspnea in the advanced
cancer setting have been conducted. These studies are
particularly difficult to complete because the patients with
advanced cancer and dyspnea are often in distress and have
a poor performance status and short survival. The paucity of
high-quality data, coupled with variability in trial design,
study interventions, and outcomes, poses a challenge to
formulating a set of recommendations when more evidence
is often needed. Where appropriate, data from other patient
populations may be discussed and will be explicitly stated.
A hierarchical approach to dyspnea is recommended,
beginning with ascertaining if there are potentially revers-
ible causes, followed by the use of nonpharmacologic in-
terventions, with pharmacologic interventions as the final
additions to a treatment plan (Figs 1-3). In this guideline,
we discuss interventions in descending order from non-
pharmacologic to pharmacologic and from most benefit
with least adverse effects to those with more potential
adverse effects.
GUIDELINE QUESTIONS
This clinical practice guideline addresses five clinical
questions: (1) how should dyspnea be assessed in patients
THE BOTTOM LINE (CONTINUED)
4.6. Other nonpharmacologicmeasures such as breathing techniques, posture, relaxation, distraction, meditation, self-
management, physical therapy, and music therapy may be offered (type: evidence-based; evidence quality: low;
strength of recommendation: weak).
4.7. Acupressure or reflexology, if available, may be offered (type: evidence-based; evidence quality: low; strength of
recommendation: weak).
4.8. Evidence remains insufficient for a recommendation for or against pulmonary rehabilitation in patients with
advanced cancer and dyspnea.
5. Pharmacologic interventions
5.1. Systemic opioids should be offered to patients with dyspnea when nonpharmacologic interventions are insufficient
to provide dyspnea relief (type: evidence-based; evidence quality: low; strength of recommendation: moderate).
5.2. Short-acting benzodiazepines may be offered to patients who experience dyspnea-related anxiety and continue to
experience dyspnea despite opioids and other nonpharmacologic measures (type: evidence-based; evidence
quality: low; strength of recommendation: weak).
5.3. Systemic corticosteroids may be offered to select patients with airway obstruction or when inflammation is likely a
key contributor of dyspnea (type: evidence-based; evidence quality: low; strength of recommendation: weak).
5.4. Bronchodilators should be used for palliation of dyspnea when patients have established obstructive pulmonary
disorders or evidence of bronchospasm (type: evidence-based; evidence quality: low; strength of recommen-
dation: weak).
5.5. Evidence remains insufficient for a recommendation for or against the use of antidepressants, neuroleptics, or
inhaled furosemide for dyspnea.
5.6. Continuous palliative sedation should be offered to patients with dyspnea that is refractory to all standard treatment
options and all applicable palliative options, and who have an expected life expectancy of days (type: informal
consensus; evidence quality: low; strength of recommendation: moderate).
Note. Table 2 and Figures 1-3 illustrate how these management strategies can be applied in different settings.
Additional Resources
More information, including a supplement, slide sets, and clinical tools and resources, is available at www.asco.org/
supportive-care-guidelines. The Methodology Manual (available at www.asco.org/guideline-methodology) provides addi-
tional information about the methods used to develop this guideline. Patient information is available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.
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with advanced cancer? (2) what underlying conditions
cause or contribute to dyspnea and warrant specific
management? (3) what is the role of palliative care in the
management of dyspnea? (4) what nonpharmacologic in-
terventions provide palliation of dyspnea? (5) what phar-
macologic interventions provide palliation of dyspnea?
METHODS
Guideline Development Process
This systematic review-based guideline was developed by a
multidisciplinary Expert Panel, which included a patient
representative and an ASCO guidelines staff member with
health researchmethodology expertise. The Expert Panelmet
via teleconference and/or webinar and corresponded through
e-mail. Based upon the consideration of the evidence, the
authors were asked to contribute to the development of the
guideline, provide critical review, and finalize the guideline
recommendations. The guideline recommendations were
sent for an open comment period of 2 weeks allowing the
public to review and comment on the recommendations after
submitting a confidentiality agreement. These comments
were taken into consideration while finalizing the recom-
mendations. Members of the Expert Panel were responsible
for reviewing and approving the penultimate version of the
guideline, which was then circulated for external review, and
submitted to the Journal of Clinical Oncology (JCO) for edi-
torial review and consideration for publication. All ASCO
guidelines are ultimately reviewed and approved by the
Expert Panel and the ASCO Clinical Practice Guidelines
Committee before publication. All funding for the adminis-
tration of the guideline was provided by ASCO. Funding for
the AHRQ systematic review was provided by the Patient-
Centered Outcomes Research Institute (PCORI).
For the questions on dyspnea assessment, management of
underlying conditions, and the role of palliative care in the
management of dyspnea (questions 1-3), PubMed and the
Cochrane Library were searched through July 31, 2020,
with no restriction on start date. Articles were selected
based on the following criteria:
• Population: patients $ 18 years of age with advanced
cancer (unlikely to be cured or controlled with treat-
ment) and breathlessness.
• Interventions: assessment of dyspnea, management of
underlying conditions, and specialty palliative care or
breathlessness services.
• Study designs: systematic reviews, clinical practice
guidelines, and RCTs.
Articles were excluded from the systematic review if they
were (1) meeting abstracts not subsequently published in
peer-reviewed journals; (2) editorials, commentaries, let-
ters, news articles, case reports, narrative reviews, or RCTs
included in eligible systematic reviews; or (3) published in a
non-English language.
Definitions of key terms are provided in Table 1. Search
terms are provided in the Data Supplement. When little or
no direct evidence was available, the panel considered the
TABLE 1. Definitions
Term Definition
Advanced cancer The American Cancer Society defines advanced cancer as cancers that cannot be cured, and metastatic cancer as
tumors that have usually spread from where they started to other parts of the body.180 However, not all advanced
cancers aremetastatic. For example, brain tumorsmay be considered advanced because they are often not curable,
even in the absence of metastasis.1
In this guideline, particular emphasis was placed on studies including patients with advanced cancer. Other patient
populations were also considered when formulating the recommendations.
Dyspnea The American Thoracic Society defines dyspnea as “a subjective experience of breathing discomfort that consists of
qualitatively distinct sensations that vary in intensity.” In this guideline, dyspnea is considered to be equivalent to
breathlessness and air hunger.1
High-Flow Nasal Cannula
(HFNC)
Delivers a humidified, heated, air oxygen blend (allowing from 21% to 100% fraction of inspired oxygen) generating up
to 60 L/min flow rates through a large-diameter nasal cannula.
Hypercapnia PaCO2 $ 45 mmHg
Hypoxemia Oxygen saturation (SpO2) , 90% while breathing room air at rest, which is equivalent to PaO2 of , 60 mmHg.
Morphine-equivalent daily
dose (MEDD)
The total dose of opioid use per 24-hour period, taking into account both the scheduled and rescue doses. To facilitate
this calculation, different opioids can be converted to oral morphine equivalents using standardized ratios. Fifteen
milligram of oral morphine is equivalent to 3.75 mg of oral hydromorphone, 5 mg of oral oxymorphone, 10 mg of oral
oxycodone, and 15mg of hydrocodone.181 Parenteral opioids are generally 2-33 as strong as their oral counterparts.
Noninvasive ventilation The American Thoracic Society and European Respiratory Society Guideline defines noninvasive ventilation as
“noninvasive variable positive airway pressure (most commonly ‘bilevel’) devices consisting of a higher inspiratory
positive airway pressure and a lower expiratory pressure as well as continuous positive airway pressure (CPAP)
delivered using various nasal, oronasal, and facial interfaces.”182(p2)
Standard supplemental oxygen Conventional oxygen therapy delivered via nasal cannula or facemasks, which can achieve flow rates of up to 15 L/min.
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appropriateness of providing good practice statements
based on discussion and criteria provided by the GRADE
Working Group.13 The ASCO guidelines program has not yet
fully transitioned to using GRADE for guideline develop-
ment, but this effort represents a step in that direction.
Good practice statements are recommendations that are
important and actionable but not appropriate for formal
ratings of the quality of the evidence.13
The evidence base for the recommendations on the
treatment of dyspnea was provided by the AHRQ sys-
tematic review.11,12 PubMed, Embase, CINAHL, ISI Web of
Science, and the Cochrane Central Register of Controlled
Trials were searched through early May 2020, with no
restriction on start date. Articles were selected based on the
following criteria:
• Population: patients $ 18 years of age with advanced
cancer (unlikely to be cured or controlled with treat-
ment) and breathlessness. Restricted to studies in
which at least half of the patients had cancer or studies
that provided cancer-specific results.
• Interventions: nonpharmacologic or pharmacologic
interventions for the palliation of dyspnea.
Routine dyspnea screening in
outpatient setting (every visit)
Further assessment






Specialist palliative care referral if
available Airflow or fan
Acupressure or reflexology 





Opioids (typically oral for everyday
dyspnea or prophylaxis of exertional
dyspnea) 
Benzodiazepines if severe anxiety
Corticosteroids if structural causes
Bronchodilators if bronchospasm
Stepwise management
In descending order of preference:
In descending order of preference:
Basic Measures Advanced Measures
High-flow oxygen at home, especially
if severely hypoxemic
Noninvasive ventilation at home,
especially if hypercapneic
FIG 1. Outpatient management of chronic dyspnea. In the ambulatory setting, patients may present with chronic dyspnea that may limit their daily
activities. A hierarchical approach is recommended to introduce interventions in a stepwisemanner to include treatment of reversible causes, a palliative
care consultation, nonpharmacologic measures, and pharmacologic measures. Opioids, if required, are mostly available in oral route, although
subcutaneous route is also possible. Regularly scheduled opioids may be useful for everyday dyspnea and prophylactic opioids may be considered
before exertion. Although home versions of high-flow nasal cannula and noninvasive ventilation are not to be routinely provided, theymay be appropriate
for selected individuals (light orange).
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• Study designs: RCTs and observational studies with
concurrent comparison groups.
• Sample size: $ 10 patients per arm.
Articles were excluded from the systematic reviews if they
were (1) meeting abstracts not subsequently published in
peer-reviewed journals; (2) editorials, commentaries, let-
ters, news articles, case reports, and narrative reviews; (3)
published in a non-English language.
The guideline recommendations were crafted, in part,
using the Guidelines Into Decision Support (GLIDES)
methodology and accompanying BRIDGE-Wiz software.14
In addition, a guideline implementability review was con-
ducted. Based on the implementability review, revisions
were made to the draft to clarify recommended actions for
clinical practice. Ratings for the type and strength of rec-
ommendation, evidence, and potential bias are provided
with each recommendation.
The ASCO Expert Panel and guidelines staff will work with
cochairs to keep abreast of any substantive updates to the
guideline. Based on formal review of the emerging literature,
ASCO will determine the need to update. The ASCO
GuidelinesMethodologyManual (available at www.asco.org/
guideline-methodology) provides additional information
about the guideline update process. This is the most recent
information as of the publication date.
Guideline Disclaimer
The Clinical Practice Guidelines and other guidance
published herein are provided by the American Society of
Clinical Oncology, Inc (ASCO) to assist providers in clinical
decision making. The information herein should not be
relied upon as being complete or accurate, nor should it be
considered as inclusive of all proper treatments or methods
of care or as a statement of the standard of care. With the
rapid development of scientific knowledge, new evidence
Routine dyspnea screening in
inpatient setting (daily)
Further assessment






Acupressure or reflexology 
Supplemental O2 if hypoxemic






High-flow oxygen, especially if severely
hypoxemic and goal concordant 
Noninvasive ventilation, especially if
hypercapneic and goal concordant
In descending order of preference:
Concurrent  management
Pharmacologic measures
Basic Measures Advanced Measures
Opioids (typically parenteral route
for treatment of acute dyspnea)
Benzodiazepines if severe anxiety
Bronchodilators if bronchospasm
Corticosteroids if structural causes
In descending order of preference:
FIG 2. Inpatient management of acute severe dyspnea. In the hospital setting, patients may report acute dyspnea, which requires more urgent attention.
Instead of a stepwise trial, clinicians may consider a concurrent approach to treat any reversible causes while providing palliation. Under close monitoring,
patients could try different interventions and identify the most effective strategies. Medications may be given parenterally for rapid treatment of dyspnea.
Supplemental oxygen, including high-flow nasal cannula and noninvasive ventilation, may be necessary for patients with hypoxemic or hypercapnic
respiratory failure.
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may emerge between the time information is developed
and when it is published or read. The information is not
continually updated and may not reflect the most recent
evidence. The information addresses only the topics
specifically identified therein and is not applicable to other
interventions, diseases, or stages of diseases. This in-
formation does not mandate any particular course of
medical care. Further, the information is not intended to
substitute for the independent professional judgment of
the treating provider, as the information does not account
for individual variation among patients. Recommenda-
tions reflect high, moderate, or low confidence that the
recommendation reflects the net effect of a given course of
action. The use of words like “must,” “must not,”
“should,” and “should not” indicates that a course of
action is recommended or not recommended for either
most or many patients, but there is latitude for the treating
clinician to select other courses of action in individual
cases. In all cases, the selected course of action should be
considered by the treating provider in the context of
treating the individual patient. Use of the information is
voluntary. ASCO provides this information on an as is basis
and makes no warranty, express or implied, regarding the
information. ASCO specifically disclaims any warranties of
merchantability or fitness for a particular use or purpose.
ASCO assumes no responsibility for any injury or damage
to persons or property arising out of or related to any use of
this information, or for any errors or omissions.
Guideline and Conflicts of Interest
The Expert Panel was assembled in accordance with
ASCO’s Conflict of Interest Policy Implementation for
Clinical Practice Guidelines (“Policy,” found at http://





Treatment of underlying cause(s)
Nonpharmacologic measures
Pharmacologic measures




Acupressure or reflexology 
Supplemental O2 if hypoxemic






High-flow oxygen, especially if severely
hypoxemic and goal concordant
Noninvasive ventilation, especially if
hypercapneic and goal concordant
Opioids
Benzodiazepines if severe anxiety
Corticosteroids if structural causes
Bronchodilators if bronchospasm
Palliative sedation if refractory
dyspnea despite all measures
In descending order of preference:
In descending order of preference:
Concurrent  management
Basic Measures Advanced Measures
FIG 3. Inpatient management of patients with dyspnea in the last days of life. Patients in the last days of life often have severe dyspnea requiring
hospitalization. A palliative care consultation is essential. Delirium and drowsiness may complicate symptom assessment and goals-of-care discussions.
The short life expectancy increases the urgency to alleviate dyspnea andmay limit the role of other therapies, such as cancer treatments, self-management
strategies, and physical therapy (light orange). Palliative sedation is a potential option for highly selected patients with refractory dyspnea. RDOS, Re-
spiratory Distress Observation Scale.
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completed ASCO’s disclosure form, which requires dis-
closure of financial and other interests, including rela-
tionships with commercial entities that are reasonably likely
to experience direct regulatory or commercial impact as a
result of promulgation of the guideline. Categories for
disclosure include employment; leadership; stock or other
ownership; honoraria, consulting or advisory role; speaker’s
bureau; research funding; patents, royalties, other intel-
lectual property; expert testimony; travel, accommodations,
expenses; and other relationships. In accordance with the
Policy, the majority of the members of the Expert Panel did
not disclose any relationships constituting a conflict under
the Policy.
RESULTS
The review conducted for the first three clinical questions
(assessment of dyspnea, management of reversible causes
of dyspnea, and referral to palliative care and/or specialty
breathlessness services) included six publications: four
systematic reviews15-18 and two guidelines.1,19
The AHRQ systematic review on the treatment of dyspnea
(questions 4-5) included 48 RCTs and two retrospective
cohort studies.11,12 Twenty-nine RCTs (2,423 patients)
addressed the comparative benefits of nonpharmacologic
interventions20-48; 17 RCTs and 1 retrospective cohort study
(1,224 patients) addressed the comparative benefits of
pharmacologic interventions49-66; and two RCTs (287 pa-
tients) addressed the comparative benefits of non-
pharmacologic, pharmacologic, and multimodal
interventions.67,68 Strength of evidence ranged from in-
sufficient to moderate, and was low for many of the
interventions.
RECOMMENDATIONS
Clinical Question 1: How Should Dyspnea Be Assessed in
Patients With Advanced Cancer?
Recommendation 1.1. Clinicians should perform system-
atic assessment of dyspnea at every inpatient and outpa-
tient encounter in patients with advanced cancer using
validated patient-reported outcome measures (good
practice statement).
Recommendation 1.2. For patients who are unable to self-
report, clinicians should use a validated observation
measure. (good practice statement).
Recommendation 1.3. Whenever possible, patients with
dyspnea should undergo a comprehensive evaluation for
the severity, chronicity, potential causes, triggers, and
associated symptoms, as well as emotional and functional
impact (good practice statement).
Literature review and analysis. Systematic reviews have
reported on several validated tools for the assessment of
dyspnea in patients with cancer and other conditions.15,17,18
Guidelines by the American Thoracic Society1 and the
European Society for Medical Oncology19 discuss the im-
portance of assessing and characterizing dyspnea.
Clinical interpretation. Because dyspnea is a subjective
experience, patient-reported outcomes represent the gold
standard for its assessment.1 Dyspnea should be distin-
guished from hypoxemia. Patients with hypoxemia may not
always be dyspneic and patients with dyspnea are often not
hypoxemic.69 Likewise, people with tachypnea may not feel
breathless, and people with breathlessness may not have
tachypnea.69
Commonly used patient-reported outcome measures for
screening of dyspnea include the 0-10 Numeric Rating
Scale, 0-10 modified Borg Scale, and the vertical 0-
100 mm Visual Analog Scale, in which a higher number
indicates worse dyspnea (Data Supplement).70-72 The an-
chors for these scales can be selected to capture dyspnea
intensity, unpleasantness, or distress.73 These unidimen-
sional outcomes have been validated in both clinical and
research settings, are quick to administer (seconds to
minutes), and relatively easy to understand and interpret for
patients and clinicians. Patients may already be familiar
with the Edmonton Symptom Assessment System, a
multisymptom battery that uses the Numeric Rating Scale
to measure 10 common symptoms including dyspnea
(Data Supplement).74,75
In addition to the above scales, the modified Medical
Research Council Breathlessness Scale may be added to
assess dyspnea severity in relation to daily activity.76 A
personalized dyspnea goal “At what level would you feel
comfortable?” may also be assessed to set individualized
targets for dyspnea interventions.77,78
Patients who are delirious, comatose, near death, or
intubated may not be able to report symptoms.79 The
Respiratory Distress Observation Scale has been validated
across diagnoses and settings of care (Data
Supplement).80-84 It consists of eight variables, including
heart rate, respiratory rate, restlessness or nonpurposeful
movements, paradoxical breathing, accessory muscle use,
grunting at end-expiration, nasal flaring, and look of fear.
Other proxy rating measures such as the Integrated Palli-
ative Care Outcome Scale may also be considered.85
Patients with episodic dyspnea should be asked about
common triggers, such as activities (eg, walking, climbing
stairs, running, bathing, and dressing), positions, weather,
pollens, and emotional distress.86 Symptoms associated
with dyspnea may include, but are not limited to, de-
pression, anxiety, fatigue, wheezing, and cough. Assess-
ment of functional impact may include questions related to
activities of daily living and performance status. Structured
exercise tests including 6-minute walk test and shuttle walk
test may provide further documentation of functional im-
pairment because of dyspnea.87,88
Objective tests such as vital signs, pulmonary function
tests, and imaging are complementary but do not replace
1396 © 2021 by American Society of Clinical Oncology Volume 39, Issue 12
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patient-reported outcomes in patients who can self-report.
However, they may have a role in identifying underlying
causes of dyspnea (eg, bronchospasm and malignant
pericardial effusion).
Clinical Question 2: What Underlying Conditions Cause or
Contribute to Dyspnea and Warrant
Specific Management?
Recommendation 2.1. Patients with potentially reversible,
common etiologies of dyspnea such as pleural effusion,
pneumonia, airway obstruction, anemia, asthma, chronic
obstructive pulmonary disease (COPD) exacerbation, pul-
monary embolism, or treatment-induced pneumonitis
should be given goal-concordant treatment(s) consistent
with their wishes, prognosis, and overall health status (good
practice statement).
Recommendation 2.2. Patients with dyspnea because of
underlying malignancy (eg, lymphangitic carcinomatosis,
atelectasis because of large pulmonary mass, and malig-
nant pleural effusion) may benefit from cancer-directed
treatments if consistent with their wishes, prognosis, and
overall health status (good practice statement).
Recommendation 2.3 Patients with underlying comorbid-
ities such as COPD or heart failure should have the
management of these conditions optimized (good practice
statement).
Literature review and analysis. Included publications did
not directly address the effect of managing underlying
causes of dyspnea, but two included guidelines noted that
management of these conditions is an important initial step
in dyspnea management.1,19
Clinical interpretation. In patients with advanced cancer,
dyspnea is often multifactorial in nature with a combination
of acute and chronic causes. For instance, a patient with
metastatic lung cancer may experience chronic dyspnea
related to lung mass compressing on mediastinum, atel-
ectasis, pleural effusion, cachexia, COPD, and anxiety, with
acute worsening because of coronavirus disease 2019
infection. Acute causes of dyspnea such as pneumonia,
pulmonary embolism, decompensated heart failure, severe
anemia, and COPD exacerbations should be managed
according to standard of care. Dyspnea related to malig-
nant pleural effusion, pericardial effusion and tamponade,
and ascites may improve significantly with drainage.89
Bronchoscopic interventions may be effective in alleviat-
ing dyspnea because of malignant central airway ob-
struction.90 A full discussion of underlying causes is beyond
the scope of this guideline.
For select patients with advanced cancer, systemic therapy
may result in tumor response, contributing to symptomatic
improvement.91 Some malignancies are highly sensitive to
systemic therapies, such as small-cell lung cancer and
selected non–small-cell lung cancer with certain targetable
mutations. Radiationmay be useful for localized obstructing
lesions or hemoptysis. At the same time, cancer treatments
may contribute to significant adverse effects and thus the
risks and benefits should always be carefully balanced,
particularly in patients with limited life expectancy.
Patients with advanced cancer often have multiple
comorbidities, which can contribute to greater symptom
burden. For example, more than 50% of patients with lung
cancer have a diagnosis of COPD, and the presence of COPD
is associated with worse survival.92-94 Optimal treatment of
comorbid diagnoses is essential to alleviating dyspnea.
Management of these comorbidities is beyond the scope of
this guideline. Readers are encouraged to refer to specific
clinical practice guidelines for the management of these
conditions.95,96 Primary care clinicians and/or other spe-
cialists such as pulmonologists should be actively engaged in
the optimization of these comorbidities if not already.
Clinical Question 3: What Is the Role of Palliative Care in
the Management of Dyspnea?
Recommendation 3. Patients with advanced cancer and
dyspnea should be referred to an interprofessional palliative
care team where available (type: evidence based; evidence
quality: intermediate; strength of recommendation: strong).
Literature review and analysis. A 2019 systematic review
and meta-analysis evaluated holistic services for patients
with advanced disease and chronic breathlessness.16
Holistic breathlessness services were defined as services
in which patients were enrolled because of their breath-
lessness and that drew on skills from multiple disciplines to
provide nonpharmacologic and pharmacologic interven-
tions as well as self-management. The 18 specific
breathlessness services that were included were all outside
the United States, and a majority cared for patients with
advanced cancer. The results suggested that holistic
breathlessness services may reduce distress because of
dyspnea.
Clinical interpretation. Patients with advanced cancer and
dyspnea have a limited prognosis, multiple associated
symptoms, and poor performance status.8 In addition, they
often experience psychosocial distress, spiritual and
existential concerns, and caregiver needs that should be
addressed longitudinally.97 RCTs support that involvement
of an interdisciplinary specialist palliative care team can help to
improve dyspnea, self-efficacy, and overall quality of life.28,98
Timely integration of specialist palliative care andoncologic care
has been found to improve overall quality of life and symptom
burden.99-101 Consistent with the ASCO palliative care
guideline,102 this panel supports timely referral to palliative care,
ideally starting in the outpatient setting. Systematic screening for
dyspnea may facilitate automatic referral.101,103,104
Given the multifactorial nature of dyspnea and its multi-
dimensional impact, multimodal interventions delivered by
interprofessional teams can be beneficial. The interpro-
fessional palliative care team typically includes advanced
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practice nurses, nurses, physicians, social workers,
chaplains, and pharmacists. Less often, other professionals
such as physical therapists andmental health professionals
may be part of the team. The palliative care team can
improve dyspnea and other patient outcomes bymonitoring
symptoms longitudinally; educating patients and informal
(family) caregivers about management strategies; imple-
menting an array of nonpharmacologic and pharmacologic
interventions; providing emotional, spiritual, and caregiver
support; facilitating illness understanding, complex deci-
sion making, and advance care planning; and coordinating
care with other disciplines.105
A breathlessness intervention service is a specialty dyspnea
clinic typically comprised of representatives from palliative
care, pulmonary medicine, physical and occupational
therapy, and other professions. To date, several clinical
trials involving cancer and noncancer patients reported that
these clinics are associated with improved perceived self-
efficacy for dyspnea.28,98 These clinics often offer an array
of nonpharmacologic and pharmacologic measures.
Compared to palliative care services, they are more spe-
cialized in scope but are not as widely available.106
Clinical Question 4: What Nonpharmacologic
Interventions Provide Palliation of Dyspnea?
Recommendation 4.1. Airflow interventions such as
directing a fan at the cheek (trigeminal nerve distribution)
should be offered (type: evidence-based; evidence quality:
intermediate; strength of recommendation: moderate).
Recommendation 4.2. Standard supplemental oxygen
should be available for patients with hypoxemia who are
experiencing dyspnea (ie, SpO2 # 90% on room air) (type:
evidence-based; evidence quality: intermediate; strength of
recommendation: moderate).
Recommendation 4.3. Supplemental oxygen is not recom-
mended when SpO2 . 90% (type: evidence-based; evi-
dence quality: intermediate; strength of recommendation:
moderate).
Recommendation 4.4. A time-limited therapeutic trial of
high-flow nasal cannula oxygen therapy, if available, may
be offered to patients who have significant dyspnea and
hypoxemia despite standard supplemental oxygen (type:
evidence-based; evidence quality: low; strength of rec-
ommendation: moderate).
Recommendation 4.5. A time-limited therapeutic trial of
noninvasive ventilation, if available, may be offered to
patients who have significant dyspnea despite standard
measures and do not have contraindications (type:
evidence-based; evidence quality: low; strength of rec-
ommendation: moderate).
Recommendation 4.6. Other nonpharmacologic measures
such as breathing techniques, posture, relaxation, dis-
traction, meditation, self-management, physical therapy,
and music therapy may be offered (type: evidence-based;
evidence quality: low; strength of recommendation: weak).
Recommendation 4.7. Acupressure or reflexology, if avail-
able, may be offered (type: evidence-based; evidence
quality: low; strength of recommendation: weak).
Recommendation 4.8. Evidence remains insufficient for a
recommendation for or against pulmonary rehabilitation in
patients with advanced cancer and dyspnea.
Literature review and analysis. Twenty-nine RCTs that met
inclusion criteria addressed nonpharmacologic interventions
for dyspnea.20-48 Based on threeRCTs and 115 patients,32,43,46
airflow interventions such as fans improved breathlessness
compared with usual care or sham control, with moderate
strength of evidence. Interventions that were associated with
improvements in breathlessness with low strength of evidence
were bilevel ventilation (comparedwith standard supplemental
oxygen, one RCT39), acupressure or reflexology (v sham or
usual care, two RCTs27,47), and multicomponent interventions
that combined behavioral or psychoeducational interventions,
activity or rehabilitation, and integrative medicine interventions
(v usual care, two RCTs28,48).
With respect to anxiety, exercise capacity, and health-
related quality of life (other key outcomes in the AHRQ
review11,12), the only intervention associated with im-
provement was activity or rehabilitation, which improved
exercise capacity with low strength of evidence (three
RCTs, 72 patients29,31,44).
Clinical interpretation. Movement of air over the face may
stimulate the trigeminal nerve andmodulate the sensation of
dyspnea. Randomized trials and systematic reviews report
that fan or airflow therapy is associated with clinically sig-
nificant and rapid alleviation of dyspnea.107-109 A hand-held,
battery-operated fan is portable, inexpensive, and can be
used at any time.110 A tabletop fan directed at the face may
suffice if the patient cannot hold the device. In addition,
medical air delivered by nasal cannula was also found to be
beneficial.111 Understandably, masking of patients is not
possible for fan-based interventions (and other non-
pharmacologic interventions), which could contribute to
ascertainment bias. Nevertheless, given the favorable
benefit-risk ratio for fan therapy, it represents the first-line,
nonpharmacologic measure for palliation of dyspnea. The
duration of benefit needs to be further examined.
Standard supplemental oxygen typically involves a nasal
cannula delivering 2-6 L/min of oxygen. In patients with
hypoxemia, standard supplemental oxygen is recom-
mended. Although humidification has been suggested to
reduce dry nose and nosebleed, a systematic review that
included 8,876 patients from 27 randomized trials reported
that nonhumified oxygen was associated with less bacterial
contamination and lower rates of respiratory infections and
nomore increase in dry nose and nosebleed compared with
humidified oxygen.112 Some patients only experience
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hypoxemia with exertion and may only require as needed
supplemental oxygen before or during activity, whereas
those with hypoxemia at rest may benefit from continuous
use. It should be noted that correction of hypoxemia may
not reverse dyspnea, especially if hypoxemia is not the only
contributor. In the United States, insurance may not cover
standard supplemental oxygen when the SpO2 is . 88%.
Oxygen saturation is expected to drop in the last hours
before death. It is important to carefully balance the risks
and benefits of supplemental oxygen. When there are no
signs of respiratory distress, oxygen, if in use, may be
withdrawn. Oxygen saturation monitoring may not be useful
in this setting, and clinicians should discuss risks and
benefits of treatment and provide recommendations based
on the patient’s stated goals of care.113
Although clinical trials reported no benefit of standard
supplemental oxygen compared with medical air for
dyspnea in the absence of hypoxemia, some patients in the
control group reported dyspnea relief with medical air,
which may be related to airflow.20,22,40,114,115 Although we
do not recommend routine use of standard supplemental
oxygen in nonhypoxemic patients with dyspnea, a time-
limited trial of low-flow oxygen or air may still be reasonable
for select patients, given the low risk of this intervention;
however, fan therapy should be considered first. See
Table 2 for a suggested approach to initiating standard
supplemental oxygen.
High-flow nasal cannula oxygen therapy can deliver up to
80 L/min of heated and humidified oxygen. In addition to
oxygenation, high-flow nasal cannula oxygen therapy may
alleviate dyspnea by multiple mechanisms, such as im-
proving ventilation with nasopharyngeal washout (ie, better
clearing of upper airway deadspace), stimulating the tri-
geminal nerves, augmenting positive airway pressure, re-
ducing work of breathing, and conditioning of inhaled gas
(ie, heated and humidified).116,117 A small RCT provided
preliminary evidence to support the benefit of this modality
in patients with cancer.30
Clinicians should weigh the risks and benefits of high-flow
nasal cannula oxygen therapy, considering underlying
pathophysiology, prognosis, patient preference, logistics,
and costs. Goals of treatment should always be discussed
before initiation of high-flow nasal cannula oxygen therapy.
This intervention may necessitate continued hospitalization
if the high flows cannot be achieved at home depending on
local availability. Other interventions should be
administered if high-flow nasal cannula oxygen therapy is
more burdensome than beneficial after a time-limited
therapeutic trial (typically , 1 hour).
Respiratory therapists are often involved in the day-to-day
delivery of high-flow oxygen, selecting themost appropriate
interface and titrating device settings. Setting of the device
is an important issue to consider since it may affect its
tolerance. It is important to work with the patient to choose
the proper nasal cannula (small, medium, and large), set
temperature as tolerated (generally between 34°C and
37°C), and the flow rate (usually start at 45-50 L/min but
may decrease down to 20 L/min or increase gradually up to
60 L/min, depending on the level of patient’s comfort).
Communication among the oncology, palliative care, pul-
monary medicine, and/or respiratory care teams is es-
sential to ensure interventions are aligned with the goals of
treatment.
Noninvasive ventilation can improve oxygenation and
ventilation by providing positive end-expiratory pressure
and augmenting respiratory muscles. Patients with hy-
percapnic respiratory failure are more likely to benefit from
noninvasive ventilation.39 The potential benefits should be
weighed against potential adverse events, such as skin
breakdown, muffled communication, claustrophobia, and
inability to eat. Contraindications to noninvasive ventilation
include facial trauma, decreased level of consciousness,
severe vomiting, inability to clear secretions, and severe
claustrophobia.
Clinicians should weigh the risks and benefits of nonin-
vasive ventilation, taking into account underlying patho-
physiology, prognosis, patient preference, logistics, and
costs. Goals of treatment should always be discussed
before initiation of noninvasive ventilation.118,119 Other in-
terventions should be administered if noninvasive venti-
lation is more burdensome than beneficial after a time-
limited therapeutic trial (typically , 1 hour). Clinicians
should be cautious about using noninvasive ventilation in
the last days of life because it may be more burdensome
than beneficial.119
Respiratory therapists are often involved in the day-to-day
delivery of noninvasive ventilation, selecting the most ap-
propriate interface, and titrating device settings. When
initiating noninvasive ventilation, consider starting with low
inspiratory pressure (ie, 8-10 cmH2O) and then gradually
increase as tolerated. Expiratory pressure should never be
above 6-8 cmH20 unless indicated (eg, cardiogenic
TABLE 2. Supplemental Oxygen Use
Dyspnea or
Respiratory Distress Oxygen Saturation Oxygen Indicated Other Interventions Indicated
Present , 90% Yes, start low Yes, to treat underlying cause of hypoxemia
Present $ 90% No; however, airflow alone can be beneficial Yes, to treat underlying cause of dyspnea
Absent , 90% Yes, for oxygenation purpose, unless last days of life Yes, to treat underlying cause of hypoxemia
Absent $ 90% No, consider withdrawal if in use No
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pulmonary edema). Choose the more appropriate size and
type of interfaces (ie, nasal, oronasal, total face, or
mouthpiece) based on patient tolerance and set the initial
flow rate (or ramp), according to the patient’s need. Similar
to high-flow oxygen, collaboration among oncology, palli-
ative care, pulmonary medicine, and/or respiratory care
teams is essential to ensure care is aligned with the goals of
treatment.
The evidence to support breathing techniques, posture,
relaxation or meditation, assistive devices, and education or
self-management is mixed and mostly derived from studies
in patients with COPD instead of cancer.120 However, given
these self-administered strategies are relatively simple,
inexpensive, low risk, and have some preliminary sup-
portive evidence, patients with dyspnea may be counseled
on adopting these interventions.
Breathing techniques include pursed lip, abdominal, and
timed breathing. In an unblinded randomized clinical trial,
a single 20-minute session of mindful breathing was found
to improve dyspnea in patients with cancer.121 A Cochrane
systematic review reported that exercise capacity improved
with breathing exercises; however, their effects on dyspnea
were inconsistent.120 Various postures such as relaxed
sitting, high-side lying, and standing against a wall have
been proposed to improve breathing dynamics.122
Education and self-management programs typically involve
educating patients about the nature of dyspnea, developing
coping strategies, learning about breathing techniques and
postures, providing emotional support, and setting man-
agement goals.36,123 Many programs promote optimizing
physical function through exercise training124 and activity
pacing; others incorporate mindfulness techniques such as
guided imagery and meditation. These programs are often
led by nurses and/or physical or occupational or respiratory
therapists. Although the evidence is mixed regarding these
programs, the panel considered these minimal-risk strate-
gies to have potential benefits and a trial may be considered.
The level of evidence to support acupressure and reflexology
is low, and the dose and duration for these interventions have
not been standardized. These complementary interventions
are practitioner-dependent. If considered, referral to a li-
censed therapist is warranted.
Pulmonary rehabilitation is well established in patients with
underlying cardiopulmonary disorders and should be of-
fered for individuals with these conditions. This intervention
typically involves multiple weeks of structured exercise
sessions conducted under the supervision of physical and/
or occupational therapists; other disciplines are sometimes
involved and patients are often taught some self-
management techniques. In patients with COPD, pulmo-
nary rehabilitation has been found to improve dyspnea,
fatigue, and health-related quality of life.125 Patients with
advanced cancer often have a short survival and it is un-
clear if they would derive the same benefit.
Clinical Question 5: What Pharmacologic Interventions
Provide Palliation of Dyspnea?
Pharmacologic measures should be considered in patients
with advanced cancer and acute and/or chronic dyspnea
when treatment of underlying conditions and non-
pharmacologic therapies do not yield patient relief (Rec-
ommendations 4.1-4.8). Patients presenting with acute
severe dyspnea may not have enough time for a stepwise
introduction of interventions, and a concurrent approach
with both pharmacologic and nonpharmacologic strategies
is warranted.
Recommendation 5.1. Systemic opioids should be offered
to patients with dyspnea when nonpharmacologic inter-
ventions are insufficient to provide dyspnea relief (type:
evidence-based; evidence quality: low; strength of rec-
ommendation: moderate).
Recommendation 5.2. Short-acting benzodiazepines may
be offered to patients who experience dyspnea-related
anxiety and who continue to experience dyspnea despite
opioids and other nonpharmacologic measures (type:
evidence-based; evidence quality: low; strength of rec-
ommendation: weak).
Recommendation 5.3. Systemic corticosteroids may be
offered to select patients with airway obstruction or when
inflammation is likely a key contributor of dyspnea (type:
evidence-based; evidence quality: low; strength of rec-
ommendation: weak).
Recommendation 5.4. Bronchodilators should be used for
palliation of dyspnea when patients have established ob-
structive pulmonary disorders or evidence of broncho-
spasm (type: evidence-based; evidence quality: low;
strength of recommendation: weak).
Recommendation 5.5. Evidence remains insufficient for a
recommendation for or against the use of antidepressants,
neuroleptics, or inhaled furosemide for dyspnea.
Recommendation 5.6. Continuous palliative sedation
should be offered to patients with dyspnea that is refractory
to all standard treatment options and all applicable palli-
ative options, and who have an expected life expectancy of
days (type: informal consensus; evidence quality: low;
strength of recommendation: moderate).
Literature review and analysis. Of the 17 RCTs49-65
assessing pharmacologic interventions included in the
AHRQ systematic review,11 six51,53,57,59,60,64 reported on
opioids versus placebo with respect to breathlessness.
Sample size in these studies ranged from 20 to 40, with a
total of 107 patients evaluated. With moderate strength of
evidence, opioids were no more effective than placebo at
improving breathlessness. Similarly, based on two
RCTs55,63 in 311 patients and low strength of evidence,
anxiolytics were no more effective than placebo with re-
spect to breathlessness. Only a single, small RCT
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addressed corticosteroids, and evidence was deemed in-
sufficient for a conclusion.58
Clinical interpretation. Although the systematic review fo-
cusing only on patients with cancer did not identify a benefit
for opioids, there are significant limitations to the few in-
cluded clinical trials, including small sample sizes, short
study duration, and variability in outcome measures.
Several systematic reviews concluded that opioids have a
clear pharmacologic effect when the greater literature on
opioids, including other patient populations such as COPD,
is taken into consideration; thus, we conclude that opioids
are likely to be effective.126-128 Despite the paucity of high-
quality evidence specifically in patients with advanced
cancer, the risk of inaction is greater than a recommen-
dation to support opioid use because dyspnea is extremely
distressing and many patients continue to experience
dyspnea despite optimal nonpharmacologic therapies.
Thus, the panel endorses a time trial of opioids for dyspnea.
There is insufficient evidence to inform the choice of opioid.
However, the choice of systemic opioid, route (eg, intra-
venous, subcutaneous, oral, rectal, and transmucosal),
and formulation should be guided by what opioids patients
are already taking, comorbidities (eg, renal insufficiency),
risk profile (eg, nonmedical opioid use), its effect on
dyspnea and adverse effects, clinical setting (inpatient v
outpatient), and logistical considerations (eg, financial).
More RCTs on dyspnea have examined morphine and
fentanyl. No studies have definitively confirmed the effect of
hydromorphone, oxycodone, methadone, or hydrocodone
on dyspnea. For patients in the last days of life who have
difficulty swallowing, opioids can be administered via the
intravenous route, subcutaneous route, transmucosal
route, or rectal route (eg, suppositories). Concentrated
morphine sulfate elixir may also be placed in the buccal
space.129 Despite mixed evidence, nebulized opioids may
also be considered in selected patients in whom systemic
opioids are not feasible.126,130
Insufficient evidence on the optimal dosing regimen of
opioids for the management of dyspnea exists. The general
principles are to start low and titrate over time to desired
effect. Optimal dosing of opioids should be informed by
pharmacokinetics and the clinical context.
Opioids may be considered in three clinical situations.
Given the paucity of data, the doses are for general ref-
erences only.131
• For hospitalized patients with acute severe dyspnea,
parenteral (subcutaneous or intravenous) opioids
should be provided. For patients who are opioid-naive,
parenteral morphine 2 mg or equivalent may be used
on an as-needed basis. For patients who are opioid-
tolerant and continue to experience dyspnea, a rescue
opioid dose equivalent to 10%-25% of morphine-
equivalent daily dose (MEDD) has been used in
clinical trials.
• For ambulatory patients with activity-induced dyspnea,
short-acting oral or rapid-acting transmucosal opioids
may be considered before selected activities for pro-
phylaxis. For patients who are opioid-naive, single
doses of MEDD of 5-10 mg orally may be used. For
patients who are opioid-tolerant who continue to ex-
perience dyspnea, a rescue opioid dose equivalent to
15%-45% of MEDD may be appropriate before ac-
tivities. The dose of opioid should be timed in relation
to the pharmacokinetic profile of the opioid (eg, 30
minutes before activity for oral immediate release
opioids).
• For patients with chronic breathlessness, scheduled
short-acting opioids or long-acting opioids may be
offered. For patients who are opioid-naive, the starting
dose is typically morphine sulfate 10-30 mg orally per
day.132 For patients who are opioid-tolerant who
continue to experience dyspnea, an increase in their
basal opioid dose by 30% may be appropriate. The
upper limit of opioid dose is based on adverse effects
(eg, neurotoxicities).
The duration of opioid use should be based on the risk-
benefit ratio, with the use of opioids regularly evaluated to
ensure the ratio remains favorable. When first using opioids
for dyspnea, a time trial should be considered with close
monitoring to evaluate derived benefits and/or adverse
effects. The opioid doses may be titrated up or down every
3-4 days in the outpatient setting or daily in the inpatient
setting to optimize patient outcomes.
Opioids are associated with many known adverse effects,
such as constipation, nausea, drowsiness, pruritus, bron-
chospasm, and nonmedical opioid use.133 Nausea and
drowsiness often abate after a few days; however, con-
stipation never abates. Clinicians should educate patients
and informal caregivers regarding the risks and benefits of
opioid therapy and the safe use, storage, and disposal of
controlled substances (see ASCO chronic pain guide-
line134) as well as educated on appropriate preventative
strategies, such as the use of stimulant laxatives for con-
stipation prophylaxis. Some patients and clinicians are
concerned about the risk of respiratory depression with
opioid use. In a meta-analysis that included 63 articles and
more than 1,000 patients, the investigators found no evi-
dence of significant or clinically relevant respiratory adverse
effects when opioids are prescribed and used properly for
chronic dyspnea.135
The literature on inhaled or nebulized opioids is limited and
mixed in both the oncology and nononcology settings. Oral
and parenteral routes are preferred over the inhaled route
because of reliable drug delivery and literature support for
clinical efficacy. However, these routes may not be possible
or feasible in some patients and the inhaled route may be
considered in select patients. In one before-after trial,
fentanyl 25 mcg in 2 cm3 normal saline by nebulizer was
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reported useful among patients cared for in an inpatient
palliative care unit.136
In general, the use of benzodiazepines in patients with ad-
vanced cancer should beminimized because of their sedative
effect, and patients with dyspnea are often already at high risk
of delirium.137 Moreover, concurrent use of benzodiazepines
and opioids or other psychotropic medications may further
increase the adverse effects, including the risk of respiratory
depression.138,139 Therefore, benzodiazepines should not be
offered as first-line treatment of dyspnea. Although benzo-
diazepines have not been demonstrated to be better than
placebo in the systematic reviews, the panel recognizes that
some patients with severe anxiety or distress related to
dyspnea despite other interventions may benefit from a trial of
benzodiazepines, given the risk of inaction is higher. In such
situations, short-acting benzodiazepines such as midazolam
2-5 mg q4h have been used in clinical trials.61,62
To date, only one small pilot study has examined the effect
of dexamethasone on dyspnea as the primary outcome in
patients with cancer. Dexamethasone 8 mg PO twice daily
was associated with an improvement of dyspnea within the
first 4 days compared with placebo.58 A large confirmatory
trial is ongoing (ClinicalTrials.gov identifier: NCT03367156).
Several randomized trials have examined breathlessness as
a secondary outcome. In one study, 84 patients with cancer-
related fatigue received either 4 mg dexamethasone twice
daily for 14 days or placebo. There was a trend favoring
dexamethasone for breathlessness (mean 22.16 v 20.89,
P 5 .06).140 Another randomized trial enrolled 298 patients
undergoing radiation for bone metastases. Dyspnea sig-
nificantly improved with dexamethasone 8 mg daily for
5 days (mean 20.3 v 2.8, P 5 .02). Dexamethasone also
improved radiation-induced pain flare.141 A few small case
reports or series reported that corticosteroids may be par-
ticularly helpful for central airway obstruction, lymphangitic
carcinomatosis, and superior vena cava syndrome.142,143
Nevertheless, no randomized trials have been conducted
to specifically examine these conditions.
Short-term systemic corticosteroids (eg, dexamethasone 8-
16 mg/d for 1 week) may be considered in select patients,
with close monitoring to assess if they experience any
benefits or adverse effects. A small prospective observa-
tional study examined predictors of response to cortico-
steroids. Patients with high baseline dyspnea scores ($ 7/
10), better prognosis (Palliative Prognostic Index, 6), and
no liver or ascites involvement were more likely to derive a
benefit.144 Corticosteroids are associated with significant
short-term (eg, hyperglycemia, hiccups, facial flushing,
dyspepsia, and insomnia) and long-term (eg, hypertension,
edema, muscle wasting, and immunosuppression) adverse
effects. They may also affect the efficacy of immunotherapy
and radiotherapy.145,146
Patients who were prescribed bronchodilators for COPD
and asthma should continue with their use (see
Recommendation 2.3). However, bronchodilators should
not be used in patients without evidence of broncho-
spasm. If used, bronchodilators should not exceed the
maximum daily dose. Supratherapeutic doses may re-
duce the bronchodilator effects while increasing the
cardiovascular adverse effects.147 A detailed discussion
of bronchodilators is beyond the scope of this guideline
and discussed elsewhere.96
Several clinical trials have examined the effect of antide-
pressants on dyspnea, including sertraline, nortriptyline,
paroxetine, and protriptyline, mostly in patients with
COPD.148-152 Some studies only enrolled patients with
depression, whereas others were less restrictive. A majority
of randomized trials did not demonstrate superiority of
antidepressants over placebo and only a few of these
randomized trials included patients with cancer.
Randomized trials have examined the effects of pro-
chlorperazine, promethazine, and chlorpromazine on
dyspnea with inconsistent findings.153-155 Neuroleptics may
be associated with side effects and should not be used
outside of a clinical trial setting.
Two small randomized trials of inhaled furosemide in pa-
tients with cancer did not identify a benefit.156,157 Adverse
effects of inhaled furosemide may include pharyngeal ir-
ritation, cough, and polyuria.
For hospitalized patients with refractory dyspnea despite all
standard measures, continuous palliative sedation may be
considered in select cases. The goal of palliative sedation is
to alleviate suffering. Some patients may be reassured that
this option is available if their dyspnea became extremely
severe, even if they may never have to use it. Two studies
found that palliative sedation did not shorten survival.158,159
A detailed discussion of palliative sedation is beyond the
scope of this guideline and discussed elsewhere.160 Spe-
cialist palliative care teams should be involved in facilitating
the complex communication and medication administra-
tion in this setting. The most common medication for
palliative sedation is midazolam infusion to provide con-
tinuous deep sedation. Before initiation of palliative seda-
tion, the healthcare team should have an extensive
discussion with patients (if able to retain decision-making
capacity) and caregivers about the risks and benefits.
Ethics consultation may also be helpful, if available.
DISCUSSION
Dyspnea is a challenging symptom to treat and currently,
the US Food and Drug Administration has not approved any
therapies for dyspnea.161 A paucity of high-quality evidence
exists to inform clinical decision making (see section on
Limitations of the Research and Future Research). This
guideline aims to provide state-of-the-science recommen-
dations on the management of dyspnea in the advanced
cancer setting. Although the principles of management are
the same, specific recommendations may vary in different
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settings. To that end, we have included several flow dia-
grams to highlight key differences (Figs 1-3).
Figure 1 summarizes the management of chronic dyspnea,
which is predominantly in the ambulatory setting. Sys-
tematic screening for dyspnea should be conducted at
every visit, which would facilitate early detection of dyspnea
and timely stepwise intervention. In patients who continue
to experience dyspnea despite treatment of underlying
causes, referral to specialist palliative care is warranted.
The interprofessional palliative care team not only works
with the patient to treat dyspnea and associated symptoms
but also facilitates goals-of-care discussions. Non-
pharmacologic therapies should be recommended before
a trial of pharmacologic therapies such as opioids. In
the ambulatory setting, oral opioids are used for treatment
of everyday dyspnea and/or prophylaxis of exertional
dyspnea.
Figure 2 outlines the management of acute dyspnea, which
is mostly in the inpatient setting. Systematic daily screening
is recommended. Given the acute and severe nature of
dyspnea, interventions should be introduced concurrently
instead of in a stepwise manner. For patients who remain
hypoxemic despite standard supplemental oxygen, high-
flow oxygen and noninvasive ventilation may be consid-
ered. Home versions of these devices are available at
discharge if required. In contrast to the ambulatory setting,
hospitalized patients may require parenteral opioids for
treatment of acute episodes of dyspnea via continuous
infusion and/or boluses.
Figure 3 outlines management of terminal dyspnea in-
volving patients in the last days of life. In this setting, pa-
tients are often delirious and may not be able to
communicate their concerns and make decisions. Some
patients may be intubated in the critical care unit. In-
volvement of the surrogate decision maker in patients who
have lost their decision-making capacity is critical. Al-
though some patients may still benefit from treatment of
underlying causes, the risks of treatment often outweigh the
benefits in this setting and further cancer treatments are no
longer recommended in these patients. Similarly, many
nonpharmacologic interventions such as self-management
may not be feasible. Given the limited time, rapid titration of
pharmacologic therapies is often necessary to maximize
comfort. In patients with refractory dyspnea and severe
distress, palliative sedation may be considered as a last
resort.
PATIENT AND CLINICIAN COMMUNICATION
For general recommendations and strategies to optimize
patient-clinician communication, see Patient-Clinician
Communication: American Society of Clinical Oncology
Consensus Guideline.162
Because dyspnea in the advanced cancer setting, by na-
ture, involves patients with greater distress, poorer function,
and worse survival, many of the decisions regarding in-
vestigations and treatment need to be discussed carefully.
The management of dyspnea in patients with months of life
expectancy can be very different from patients with days of
life expectancy. As discussed above, it is important to set
realistic expectations for what can be achieved, setting a
time to revisit the decision after a short trial, and ensure the
management approach is concordant with the goals and
wishes expressed by patients and caregivers.
Many of the nonpharmacologic approaches such as airflow
therapy and self-management require patients to be ac-
tively involved in the delivery of the interventions. Patients
need to understand the principles and concepts and feel
comfortable applying the techniques, such as activity
pacing or breathing training, and use of fans. A randomized
trial compared three breathing technique training sessions
to a single session and reported improvement in both
groups with no difference in worst dyspnea, suggesting that
a single session may be adequate.163 Initiation of high-flow
oxygen and noninvasive ventilation warrants training the
informal caregiver along with the patient.
For pharmacologic therapies, the benefit-to-risk ratio is
more variable and needs to be explored with patients and
their caregivers. A time-limited trial may be worthwhile. For
example, although opioids confer some benefits for
dyspnea, they are also associated with potential adverse
effects. Patients should be counseled on proper and safe
opioid use and storage. Some patients may be fearful about
opioids, requiring significant counseling. Others may have
significant risk factors for nonmedical opioid use, and the
benefit-to-risk ratio will need to be monitored closely.
Informal caregivers play a critical role in supporting the
patients’ physical needs, providing emotional support,
aiding with decision making, and assisting with care
planning.164 In patients who can no longer communicate
(eg, intubated and delirious patients), they serve as sur-
rogate decision makers. Informal caregivers of patients with
advanced cancer and dyspnea often have their own in-
formation needs (eg, coping and prognosis) and may ex-
perience distress related to increased caregiver burden,
exhaustion, anxiety, and uncertainty as the patients’
functional status declines.165,166 Several studies support the
role of palliative care, breathlessness intervention service,
and psychoeducational interventions for informal care-
givers; however, further research is needed.28,98
HEALTH DISPARITIES
Although ASCO clinical practice guidelines represent ex-
pert recommendations on the best practices in disease
management to provide the highest level of cancer care, it is
important to note that many patients have limited access to
medical care. Racial and ethnic disparities in health care
contribute significantly to this problem in the United States.
Patients with cancer who are members of racial or ethnic
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minorities suffer disproportionately from comorbidities,
experience more substantial obstacles to receiving care,
are more likely to be uninsured, and are at greater risk of
receiving care of poor quality compared with other
patients.167-169 Many patients lack access to care because
of their geographic location and distance from appropriate
treatment facilities. Awareness of these disparities in ac-
cess to care should be considered in the context of this
clinical practice guideline, and clinicians should strive to
deliver the highest level of cancer care to these vulnerable
populations. An updated ASCO policy statement on cancer
disparities and health equity was published in August
2020.170 The statement focuses on improving equitable
access to care, improving clinical research, addressing
structural barriers, and increasing awareness.
Few studies have addressed disparities in dyspnea man-
agement among patients with cancer, but a 2016 evalu-
ation of patients with lung or colorectal cancer enrolled in
the Cancer Care Outcomes Research and Surveillance
(CanCORS) study considered the impact of financial strain
on symptom burden.171 Among patients with lung cancer,
patients with fewer financial reserves reported worse
dyspnea measures even after adjustment for age, sex, race
or ethnicity, household income, education, health insur-
ance, cancer stage, and comorbidity. The researchers
hypothesize that this could be because of worsening dis-
ease burden, inability to access high-quality supportive
care, or difficulty obtaining medications.
MULTIPLE CHRONIC CONDITIONS
Creating evidence-based recommendations to inform
treatment of patients with additional chronic conditions, a
situation in which the patient may have two or more such
conditions—referred to as multiple chronic conditions
(MCC)—is challenging. Patients with MCC are a complex
and heterogeneous population, making it difficult to ac-
count for all of the possible permutations to develop specific
recommendations for care. In addition, the best available
evidence for treating index conditions, such as cancer, is
often from clinical trials whose study selection criteria may
exclude these patients to avoid potential interaction effects
or confounding of results associated with MCC. As a result,
the reliability of outcome data from these studies may be
limited, thereby creating constraints for expert groups to
make recommendations for care in this heterogeneous
patient population.
As many patients for whom guideline recommendations
apply present with MCC, any treatment plan needs to take
into account the complexity and uncertainty created by the
presence of MCC and highlights the importance of shared
decision making regarding guideline use and imple-
mentation. Therefore, in consideration of recommended
care for the target index condition, clinicians should review
all other chronic conditions present in the patient and take
those conditions into account when formulating the treat-
ment and follow-up plan.
In light of the above considerations, practice guidelines
should provide information on how to apply the recom-
mendations for patients with MCC, perhaps as a qualifying
statement for recommended care. This may mean that
some or all of the recommended care options are modified
or not applied, as determined by best practice in consid-
eration of any MCC.
Dyspnea is prevalent in advanced cancer and cardiopul-
monary conditions, which covary particularly among pa-
tients who used tobacco products. Among patients with
lung cancer, more than 50% were also diagnosed with
COPD.92-94 Cachexia is also highly prevalent in patients with
advanced cancer and may contribute to dyspnea sec-
ondary to atrophy of respiratory muscles and cardiac
muscular dysfunction.172,173 Last days organ failure, par-
ticularly liver and renal, will affect the efficacy of the rec-
ommended pharmacologic interventions. Involvement of
the interprofessional team and appropriate subspecialties
may be necessary to optimize management of these
comorbid conditions. The clinical implications of the rec-
ommendations in the guideline gave consideration to the
implication of MCC.
COST IMPLICATIONS
Increasingly, individuals with cancer are required to pay a
larger proportion of their treatment costs through deduct-
ibles and coinsurance.174,175 Higher patient out-of-pocket
costs have been shown to be a barrier to initiating and
adhering to recommended cancer treatments.176,177
Discussion of cost can be an important part of shared
decision making.178 Clinicians should discuss with patients
the use of less expensive alternatives when it is practical
and feasible for treatment of the patient’s disease and there
are two or more treatment options that are comparable in
terms of benefits and harms.178
Many nonpharmacologic therapies such as fan and self-
management strategies are associated with no or very
limited cost. Others such as reflexology may involve greater
expenses over multiple sessions. Prescription of opioids for
dyspnea is off label. Many of the medications for dyspnea,
such as morphine and dexamethasone, are available as
generic forms and are relatively inexpensive. Rapid-onset
fentanyl and some combination bronchodilators can be
much more expensive.
Patient out-of-pocket costs may vary depending on in-
surance coverage. Supplemental oxygen therapy in the
outpatient setting may pose a cost for the patient if the
insurance coverage is denied for an SpO2 . 88%. Cov-
erage may originate in the medical or pharmacy benefit,
which may have different cost-sharing arrangements. Pa-
tients should be aware that different products may be
preferred or covered by their particular insurance plan.
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Even with the same insurance plan, the price may vary
between different pharmacies. When discussing financial
issues and concerns, patients should bemade aware of any
financial counseling services available to address this
complex and heterogeneous landscape.178
EXTERNAL REVIEW AND OPEN COMMENT
The draft recommendations were released to the public for
open comment from September 1 to September 15, 2020.
Response categories of “Agree as written,” “Agree with
suggested modifications,” and “Disagree. See comments”
were captured for every proposed recommendation with six
written comments received. Five of the six reviewers agreed
or agreed with suggested modifications to the recom-
mendations. Expert Panel members reviewed comments
from all sources and determined whether to maintain
original draft recommendations, revise with minor language
changes, or consider major recommendation revisions. All
changes were incorporated before Center for Peace and
Global Citizenship (CPGC) review and approval.
The draft was submitted to two external reviewers with
content expertise. Review comments were reviewed by the
Expert Panel and integrated into the final manuscript before
approval by the CPGC.
GUIDELINE IMPLEMENTATION
ASCO guidelines are developed for implementation across
health settings. Each ASCO guideline includes a member
from ASCO’s Practice Guideline Implementation Network
(PGIN) on the panel. The additional role of this PGIN
representative on the guideline panel is to assess the
suitability of the recommendations to implementation in the
community setting, but also to identify any other barrier to
implementation. Barriers to implementation include the
need to increase awareness of the guideline recommen-
dations among front-line practitioners and survivors of
cancer and caregivers, and also to provide adequate ser-
vices in the face of limited resources. The guideline Bottom
Line Box was designed to facilitate implementation of
recommendations. This guideline will be distributed widely
through the ASCO PGIN. ASCO guidelines are posted on
the ASCO website and most often published in the Journal
of Clinical Oncology.
LIMITATIONS OF THE RESEARCH AND FUTURE RESEARCH
As noted above, the literature on dyspnea has major limi-
tations. We will focus our discussion here on RCTs that are
essential to inform treatment recommendations. Few clin-
ical trials have focused on cancer-related dyspnea, partly
related to the lack of funding and investigators. This is not
surprising, given that patients with advanced cancer and
dyspnea often have a poor performance status, significant
distress, and short survival, making them less likely to enroll
and stay on clinical trials. For example, attrition from clinical
trials is higher among advanced cancer patients with
dyspnea at baseline.179 This also explains why the few
clinical trials in this setting are often preliminary in nature
with a small sample size (often, 30 patients), which could
contribute to both false-negative and false-positive findings.
Other studies have tried to address the sample size concern
with a mixed population of cancer and noncancer patients,
which could complicate interpretability and generalizability.
Methodologic challenges related to dyspnea as a subjective
outcome should also be highlighted. There is increased
understanding that, similar to pain, dyspnea is not a single
entity but one with many subtypes that may require dif-
ferent treatment approaches. Specifically, dyspnea can be
classified as dyspnea at rest, episodic dyspnea, and ev-
eryday dyspnea, and also based on chronicity (acute v
chronic). Currently, many studies on everyday dyspnea
have not accounted for activity levels when assessing
dyspnea. Effective interventions for dyspnea may be de-
clared negative if they improved function or dyspnea-
related distress but not dyspnea intensity if patients tried
to do as much as they could tolerate. Response to an in-
tervention may be determined by diagnosis (eg, cancer v
noncancer) and pathophysiology (obstructive lung disease,
restrictive lung disease, mixed, and nonpulmonary). For
instance, bronchodilators have been found to be effica-
cious in patients with COPD but their role in patients with
cancer remains unclear. Furthermore, the applicability of
an intervention may be limited by settings (inpatient, out-
patient, and community) and disease trajectory (months v
weeks or days). Currently, many studies have mixed or ill-
defined patient populations, which may not allow them to
detect an adequate signal. Furthermore, different investi-
gators have chosen different patient-reported outcome
measures to assess dyspnea with different time anchors
and variable degrees of validation.17 The concept of min-
imal clinically important difference has its own limitations. It
is not often available for an instrument and when available,
may not be applicable to a specific patient population.
Response shift may further complicate interpretation. In
some studies, dyspnea is only an exploratory outcome
rather than primary end point.
Choice of study intervention and control could also have a
major impact on the outcome. There is inadequate un-
derstanding of the pathophysiology of dyspnea to develop
novel interventions. There are few dose-finding studies, and
underdosing of an intervention may contribute to negative
findings. Pharmacologic trials may include placebo control
for proper blinding, but placebo effect may be of benefit
itself, and interventions that showed within-group im-
provement but no between-group difference against pla-
cebo may be concluded as ineffective. Nonpharmacologic
studies typically are not blinded, which may represent a
source of ascertainment bias.
Taken together, the few available studies, heteroge-
neous patient populations, small sample size, choice of
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interventions and controls, and limitations with study out-
comes explain why there remain many unanswered
questions and few established interventions for dyspnea.
Below is a list of contemporary research questions:
• What is the natural history and pathophysiology of
dyspnea?
• How is dyspnea experienced in patients with cancer
compared with other populations?
• What is the optimal combination of multimodal
therapy?
• For what type of dyspnea (chronic v episodic) is an
intervention most efficacious?
• What is the most appropriate study outcome? How to
account for dyspnea and physical function at the same
time?
• How to define dyspnea response?
• Who are the patients most likely to benefit from a
specific intervention?
• What are the short- and long-term adverse effects of
treatment?
• What are the right medication, dose, dosing schedule,
and timing for treatment administration?
Given the high prevalence of this symptom in patients with
advanced cancer, its distressing nature, and functional
impact, more high-quality research is needed to develop
novel interventions to support patients and informal care-
givers. Funding agencies need to prioritize dyspnea in-
terventions to catalyze research in this area. Collaboration
among investigators would allow sharing of expertise to
optimize study designs, facilitate multicenter recruitment to
increase sample size, and maximize generalizability and
knowledge translation.
ASCO believes that cancer clinical trials are vital to inform
medical decisions and improve cancer care, and that all
patients should have the opportunity to participate.
ADDITIONAL RESOURCES
More information, including a supplement, slide sets, and
clinical tools and resources, is available at www.asco.org/
supportive-care-guidelines. Patient information is available
at www.cancer.net.
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APPENDIX
TABLE A1. Management of Dyspnea in Advanced Cancer: ASCO Guideline Expert Panel Membership
Name Affiliation or Institution Area of Expertise
David Hui, MD (cochair) MD Anderson Cancer Center, Houston, TX Medical oncology and palliative care
Margaret L. Campbell, PhD, RN
(cochair)
Wayne State University, Detroit, MI Palliative care
Ting Bao, MD Memorial Sloan Kettering Cancer Center, New York, NY Breast oncology and integrative medicine
Toby C. Campbell, MD, MS University of Wisconsin-Madison, Madison, WI Medical oncology and palliative care
Patrick J. Coyne, MSN, ACHPN,
ACNS-BC
Medical University of South Carolina, Charleston, SC Palliative care
David C. Currow, BMed, MPH, PhD University of Technology Sydney, Sydney, Australia Palliative care
Arjun Gupta, MD Johns Hopkins Sidney Kimmel Comprehensive Cancer Center,
Baltimore, MD
Medical oncology
Aliza L. Leiser, MD Rutgers RWJ Cancer Institute of New Jersey, New Brunswick,
NJ
Gynecologic oncology, PGIN representative
Masanori Mori, MD Seirei Mikatahara General Hospital, Hamamatsu, Shizuoka,
Japan
Palliative care
Stefano Nava, MD IRCCS Azienda Ospedaliera University of Bologna, S. Orsola-
Malpighi Hospital, Alma Mater University, Bologna, Italy
Respiratory medicine
Lynn F. Reinke, PhD, ARNP VA Puget Sound Health Care System, Seattle, WA Palliative care and respiratory medicine
Eric J. Roeland, MD Massachusetts General Hospital Cancer Center, Boston, MA Medical oncology and palliative care
Carole Seigel Brookline, MA Advocacy
Declan Walsh, MD, MSc Levine Cancer Institute, Charlotte, NC Medical oncology and palliative care
Kari Bohlke, ScD ASCO ASCO practice guideline staff (health research
methods)
Abbreviation: PGIN, Practice Guidelines Implementation Network.
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